References
This page is intended for Irish Healthcare Professionals only
1. Cariban, Summary of Product Characteristics (SPC)
June 2026
2. Hyperemesis and Nausea/Vomiting In Pregnancy Guidelines. Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland and the Clinical Strategy and Programmes Division, Health Service Executive.
2018
3. Saz-Leal, P. et al. Bioavailability of Cariban® Capsules: A Modified-Release Fixed-Dose Combination of Doxylamine and Pyridoxine to Relieve Nausea and Vomiting During Pregnancy. Drugs R D 23, 185–195 (2023).
https://doi.org/10.1007/s40268-023-00425-7.
4. Gadsby R, et al. Nausea and vomiting of pregnancy and resource implications: the NVP Impact Study. British Journal of General Practice 2019; 69 (680): e217-e223. DOI: https://doi.org/10.3399/bjgp18X700745
5. Lacasse, A., Bérard, A. Validation of the nausea and vomiting of pregnancy specific health related quality of life questionnaire. Health Qual Life Outcomes 6, 32 (2008).
https://doi.org/10.1186/1477-7525-6-32
6. Campbell K, Rowe H, Azzam H, Lane CA. The Management of Nausea and Vomiting of Pregnancy. J Obstet Gynaecol Can.
2016;38(12):1127-37.
7. Cariban, Patient Information Leaflet (PIL)
May 2026
8. Koren G, Clark S, Hankins GDV, et al. Effectiveness of delayed release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. Am J Obstet Gynecol
2010;203:571.e1-7.
9. RCOG GREEN-TOP GUIDELINES. The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69).
https://doi.org/10.1111/1471-0528.17739
Ensure you are viewing relevant content
Please select from the following options:
MAT-CARI-IE-000081
MAT-CARI-IE-000082
|
Date of preparation: August 2025
Mailing list sign up
Keep up to date with the latest Cariban news and information by joining our mailing list.